CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 110 enrolled
Drug / intervention
pravastatin +1 moredrug
Likely dose
pravastatin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00456365
NCT00456365Phase 3Completed
CompareCT.gov

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease

University of Colorado, Denver·interventional·Posted Apr 4, 2007·Updated Mar 9, 2018

In Brief

A Phase 3 clinical trial evaluating pravastatin and Placebo for Polycystic Kidney, Autosomal Dominant. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Kidney, Autosomal Dominant
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 4, 2007
Enrollment StartNov 1, 2006
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 19.2 years ago

Interventions

pravastatindrug

Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)

Placebodrug

Placebo daily